Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials Journal Article
| Authors: | Palomba, M. L.; Jun, M. P.; Lymp, J.; Nguyen, A.; McGarvey, N.; Gitlin, M.; Pelletier, C.; Keating, S. J.; Godwin, J. |
| Article Title: | Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials |
| Abstract: | This retrospective study estimated postinfusion health care resource utilization (HCRU) by site of care among 303 patients with relapsed/refractory large B-cell lymphoma who received third- or later-line treatment with lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH trials. Inpatients (n = 256) had higher rates of hospitalization versus outpatients (n = 47; >99% vs 62%), by definition, and higher rates of tocilizumab use for cytokine release syndrome and/or neurological events (22% vs 9%). Rates of intensive care unit admission, corticosteroid use, vasopressor use, hemodialysis, and intubation were generally low and similar between groups. Median (range) total hospital length of stay was 15 (0–88) days (inpatients) and 4 (0–77) days (outpatients). Over 6 months, estimated mean postinfusion cost of care was $89,535 (inpatients) and $36,702 (outpatients). Most costs were incurred in the first month postinfusion (inpatients, $50,369 [56%]; outpatients, $19,837 [54%]). Lower overall HCRU was observed with outpatient postinfusion monitoring. © 2021 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; cancer chemotherapy; controlled study; middle aged; major clinical study; drug tolerability; cancer recurrence; drug efficacy; drug safety; cancer patient; c reactive protein; protein bcl 2; retrospective study; hospital care; health care cost; myc protein; hospital patient; outpatient; lactate dehydrogenase; protein bcl 6; large cell lymphoma; corticosteroid; observational study; neurologic disease; hemodialysis; follicular lymphoma; lactate dehydrogenase blood level; cost; creatinine clearance; hypertensive factor; heart ejection fraction; cytokine release syndrome; diffuse large b cell lymphoma; tocilizumab; resource utilization; economic burden; human; male; female; article; car t cell therapy; lisocabtagene maraleucel; inpatient and/or outpatient monitoring; refractory large b cell lymphoma; relapse arge b cell lymphoma |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 62 |
| Issue: | 9 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2021-01-01 |
| Start Page: | 2169 |
| End Page: | 2176 |
| Language: | English |
| DOI: | 10.1080/10428194.2021.1910686 |
| PROVIDER: | scopus |
| PUBMED: | 34018458 |
| PMCID: | PMC9400457 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
